[HTML][HTML] Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 …
R Izikson, D Brune, JS Bolduc, P Bourron… - The Lancet …, 2022 - thelancet.com
Background Concomitant seasonal influenza vaccination with a COVID-19 vaccine booster
could help to minimise potential disruption to the seasonal influenza vaccination campaign …
could help to minimise potential disruption to the seasonal influenza vaccination campaign …
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a …
S Toback, E Galiza, C Cosgrove, J Galloway… - The Lancet …, 2022 - thelancet.com
Background The safety and immunogenicity profile of COVID-19 vaccines when
administered concomitantly with seasonal influenza vaccines have not yet been reported …
administered concomitantly with seasonal influenza vaccines have not yet been reported …
Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults
EJ Anderson, NG Rouphael, AT Widge… - … England Journal of …, 2020 - Mass Medical Soc
Background Testing of vaccine candidates to prevent infection with severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased …
syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased …
Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: a randomised, controlled, multicentre …
J Beran, H Reynales, A Poder, YY Charles… - The Lancet Infectious …, 2021 - thelancet.com
Background The absolute degree of protection from influenza vaccines in older adults has
not been studied since 2001. This study aimed to show the clinical efficacy of an MF59 …
not been studied since 2001. This study aimed to show the clinical efficacy of an MF59 …
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled …
Y Zhang, G Zeng, H Pan, C Li, Y Hu, K Chu… - The Lancet infectious …, 2021 - thelancet.com
Background With the unprecedented morbidity and mortality associated with the COVID-19
pandemic, a vaccine against COVID-19 is urgently needed. We investigated CoronaVac …
pandemic, a vaccine against COVID-19 is urgently needed. We investigated CoronaVac …
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind …
Z Wu, Y Hu, M Xu, Z Chen, W Yang, Z Jiang… - The Lancet Infectious …, 2021 - thelancet.com
Background A vaccine against COVID-19 is urgently needed for older adults, in whom
morbidity and mortality due to the disease are increased. We aimed to assess the safety …
morbidity and mortality due to the disease are increased. We aimed to assess the safety …
Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK …
R Lazarus, S Baos, H Cappel-Porter… - The Lancet, 2021 - thelancet.com
Background Concomitant administration of COVID-19 and influenza vaccines could reduce
burden on health-care systems. We aimed to assess the safety of concomitant administration …
burden on health-care systems. We aimed to assess the safety of concomitant administration …
[HTML][HTML] A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
L Chu, R McPhee, W Huang, H Bennett, R Pajon… - Vaccine, 2021 - Elsevier
Background Vaccines are urgently needed to prevent the global spread of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). We assessed the safety and …
respiratory syndrome coronavirus 2 (SARS-CoV-2). We assessed the safety and …
Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis …
Background Synthesising evidence on the long-term vaccine effectiveness of COVID-19
vaccines (BNT162b2 [Pfizer–BioNTech], mRNA-1273 [Moderna], ChAdOx1 nCoV-19 …
vaccines (BNT162b2 [Pfizer–BioNTech], mRNA-1273 [Moderna], ChAdOx1 nCoV-19 …
Timing and sequence of vaccination against COVID-19 and influenza (TACTIC): a single-blind, placebo-controlled randomized clinical trial
Background Novel mRNA-based vaccines have been used to protect against SARS-CoV-2,
especially in vulnerable populations who also receive an annual influenza vaccination. The …
especially in vulnerable populations who also receive an annual influenza vaccination. The …